Related Experiment Video
Updated: Jul 8, 2026
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical
Anne Vessières1, Emie Quissac2, Nolwenn Lemaire2
1Institut Parisien de Chimie Moléculaire, Sorbonne Université, CNRS, UMR CNRS 8232, 4 Place Jussieu, F-75005 Paris, France.
Abstract:
Glioblastoma (GBM) is the most frequent and deadliest primary brain cancer in adults, justifying the search for new treatments. Some members of the iron-based ferrocifen family have demonstrated a high cytotoxic effect on various cancer cell lines via innovative mechanisms of action. Here, we evaluated the antiproliferative activity by wst-1 assay of six ferrocifens in 15 molecularly diverse GBM patient-derived cell lines (PDCLs). In five out of six compounds, the half maximal inhibitory concentration (IC50) values varied significantly (10 nM < IC50 < 29.8 µM) while the remaining one (the tamoxifen-like complex) was highly cytotoxic against all PDCLs (mean IC50 = 1.28 µM). The pattern of response was comparable for the four ferrocifens bearing at least one phenol group and differed widely from those of the tamoxifen-like complex and the complex with no phenol group. An RNA sequencing differential analysis showed that response to the diphenol ferrocifen relied on the activation of the Death Receptor signaling pathway and the modulation of FAS expression. Response to this complex was greater in PDCLs from the Mesenchymal or Proneural transcriptomic subtypes compared to the ones from the Classical subtype. These results provide new information on the mechanisms of action of ferrocifens and highlight a broader diversity of behavior than previously suspected among members of this family. They also support the case for a molecular-based personalized approach to future use of ferrocifens in the treatment of GBM.
Insights
Researchers explored ferrocifen compounds against glioblastoma (GBM), a deadly brain cancer. One compound showed high cytotoxicity across GBM patient-derived cell lines, suggesting potential for personalized GBM treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Glioblastoma (GBM) is the most aggressive primary brain tumor.
- Ferrocifen compounds, iron-based molecules, exhibit potent anti-cancer properties.
- Novel therapeutic strategies are urgently needed for GBM treatment.
Purpose of the Study:
- To evaluate the antiproliferative activity of six ferrocifen compounds against GBM patient-derived cell lines (PDCLs).
- To investigate the mechanisms of action and identify predictive biomarkers for ferrocifen efficacy in GBM.
- To explore the potential of ferrocifens as a personalized treatment for GBM.
Main Methods:
- Antiproliferative activity assessed using the wst-1 assay in 15 diverse GBM PDCLs.
- Half maximal inhibitory concentration (IC50) values determined for six ferrocifen compounds.
- RNA sequencing differential analysis performed to elucidate mechanisms of action and response patterns.
Main Results:
- One ferrocifen derivative demonstrated significant cytotoxicity across all tested GBM PDCLs (mean IC50 = 1.28 µM).
- Ferrocifen response varied based on compound structure (presence of phenol groups) and GBM subtype (Mesenchymal/Proneural vs. Classical).
- Response to a diphenol ferrocifen involved activation of the Death Receptor pathway and FAS modulation.
Conclusions:
- Ferrocifens exhibit diverse anti-GBM activities, with potential for targeted therapies.
- The diphenol ferrocifen's efficacy is linked to specific molecular pathways and GBM subtypes.
- Findings support a personalized medicine approach for utilizing ferrocifens in GBM treatment.
